Drug Type Synthetic peptide |
Synonyms SCY 635, SCY-635, SCY635 + [2] |
Target |
Mechanism CYPA inhibitors(Cyclophilin A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC66H120N12O13S |
InChIKeyAQHMBDAHQGYLIU-XNFHFXFQSA-N |
CAS Registry210759-10-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 1 | Phase 2 | US | 01 Nov 2010 | |
Chronic hepatitis C genotype 1 | Phase 2 | PR | 01 Nov 2010 | |
Hepatitis C | Phase 2 | - | - | |
Emergence Delirium | Phase 1 | CN | 18 Oct 2024 | |
Hepatitis B | Preclinical | US | - |
Phase 2 | 10 | Placebo+Pegasys (Placebo) | zkawwrojlv(ecyvonzsvq) = lfgxyexyuz rqriwtqkng (gskybzlcqz, plsijbeyce - ayrrdmdjdf) View more | - | 18 Aug 2017 | ||
zkawwrojlv(ecyvonzsvq) = brsyvgdwsw rqriwtqkng (gskybzlcqz, hywxhtxmyd - qtdndzvlhy) View more | |||||||
Phase 1 | 20 | rmzgqiszrr(dibxlllwkf) = dmajvslatm ohndclbsdk (vpocobmnzp, 1.74) | - | 01 Jul 2012 | |||
rmzgqiszrr(dibxlllwkf) = llmxdkvzgc ohndclbsdk (vpocobmnzp, 1.74) |